Literature DB >> 27511855

Computational Modeling of Micrometastatic Breast Cancer Radiation Dose Response.

Daniel L Smith1, Bisrat G Debeb1, Howard D Thames2, Wendy A Woodward3.   

Abstract

PURPOSE: Prophylactic cranial irradiation (PCI) involves giving radiation to the entire brain with the goals of reducing the incidence of brain metastasis and improving overall survival. Experimentally, we have demonstrated that PCI prevents brain metastases in a breast cancer mouse model. We developed a computational model to expand on and aid in the interpretation of our experimental results. METHODS AND MATERIALS: MATLAB was used to develop a computational model of brain metastasis and PCI in mice. Model input parameters were optimized such that the model output would match the experimental number of metastases per mouse from the unirradiated group. An independent in vivo-limiting dilution experiment was performed to validate the model. The effect of whole brain irradiation at different measurement points after tumor cells were injected was evaluated in terms of the incidence, number of metastases, and tumor burden and was then compared with the corresponding experimental data.
RESULTS: In the optimized model, the correlation between the number of metastases per mouse and the experimental fits was >95. Our attempt to validate the model with a limiting dilution assay produced 99.9% correlation with respect to the incidence of metastases. The model accurately predicted the effect of whole-brain irradiation given 3 weeks after cell injection but substantially underestimated its effect when delivered 5 days after cell injection. The model further demonstrated that delaying whole-brain irradiation until the development of gross disease introduces a dose threshold that must be reached before a reduction in incidence can be realized.
CONCLUSIONS: Our computational model of mouse brain metastasis and PCI correlated strongly with our experiments with unirradiated mice. The results further suggest that early treatment of subclinical disease is more effective than irradiating established disease.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2016        PMID: 27511855      PMCID: PMC5702256          DOI: 10.1016/j.ijrobp.2016.04.014

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  19 in total

1.  Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission. Prophylactic Cranial Irradiation Overview Collaborative Group.

Authors:  A Aupérin; R Arriagada; J P Pignon; C Le Péchoux; A Gregor; R J Stephens; P E Kristjansen; B E Johnson; H Ueoka; H Wagner; J Aisner
Journal:  N Engl J Med       Date:  1999-08-12       Impact factor: 91.245

2.  Breast cancer metastasis: challenges and opportunities.

Authors:  Jing Lu; Patricia S Steeg; Janet E Price; Savitri Krishnamurthy; Sendurai A Mani; James Reuben; Massimo Cristofanilli; Gabriela Dontu; Luc Bidaut; Vicente Valero; Gabriel N Hortobagyi; Dihua Yu
Journal:  Cancer Res       Date:  2009-05-26       Impact factor: 12.701

3.  Dose-response relationship for prophylactic cranial irradiation in small cell lung cancer.

Authors:  R Suwinski; S P Lee; H R Withers
Journal:  Int J Radiat Oncol Biol Phys       Date:  1998-03-01       Impact factor: 7.038

4.  Comparison of two methods of preventing central nervous system leukemia.

Authors:  R J Aur; H O Hustu; M S Verzosa; A Wood; J V Simone
Journal:  Blood       Date:  1973-09       Impact factor: 22.113

5.  Significance of the size distribution of bloodborne metastases.

Authors:  J R Douglas
Journal:  Cancer       Date:  1971-02       Impact factor: 6.860

6.  A Gompertzian model of human breast cancer growth.

Authors:  L Norton
Journal:  Cancer Res       Date:  1988-12-15       Impact factor: 12.701

7.  Memantine for the prevention of cognitive dysfunction in patients receiving whole-brain radiotherapy: a randomized, double-blind, placebo-controlled trial.

Authors:  Paul D Brown; Stephanie Pugh; Nadia N Laack; Jeffrey S Wefel; Deepak Khuntia; Christina Meyers; Ali Choucair; Sherry Fox; John H Suh; David Roberge; Vivek Kavadi; Soren M Bentzen; Minesh P Mehta; Deborah Watkins-Bruner
Journal:  Neuro Oncol       Date:  2013-08-16       Impact factor: 12.300

8.  Mesenchymal stem cells promote mammosphere formation and decrease E-cadherin in normal and malignant breast cells.

Authors:  Ann H Klopp; Lara Lacerda; Anshul Gupta; Bisrat G Debeb; Travis Solley; Li Li; Erika Spaeth; Wei Xu; Xiaomei Zhang; Michael T Lewis; James M Reuben; Savitri Krishnamurthy; Mauro Ferrari; Rogério Gaspar; Thomas A Buchholz; Massimo Cristofanilli; Frank Marini; Michael Andreeff; Wendy A Woodward
Journal:  PLoS One       Date:  2010-08-16       Impact factor: 3.240

9.  Survival in patients with brain metastases from breast cancer: the importance of HER-2 status.

Authors:  April F Eichler; Irene Kuter; Paula Ryan; Lidia Schapira; Jerry Younger; John W Henson
Journal:  Cancer       Date:  2008-06       Impact factor: 6.860

10.  Prophylactic cranial irradiation in extensive small-cell lung cancer.

Authors:  Ben Slotman; Corinne Faivre-Finn; Gijs Kramer; Elaine Rankin; Michael Snee; Matthew Hatton; Pieter Postmus; Laurence Collette; Elena Musat; Suresh Senan
Journal:  N Engl J Med       Date:  2007-08-16       Impact factor: 91.245

View more
  6 in total

1.  NDRG1 in Aggressive Breast Cancer Progression and Brain Metastasis.

Authors:  Emilly S Villodre; Xiaoding Hu; Bedrich L Eckhardt; Richard Larson; Lei Huo; Ester C Yoon; Yun Gong; Juhee Song; Shuying Liu; Naoto T Ueno; Savitri Krishnamurthy; Stefan Pusch; Debu Tripathy; Wendy A Woodward; Bisrat G Debeb
Journal:  J Natl Cancer Inst       Date:  2022-04-11       Impact factor: 11.816

2.  Stratification of radiosensitive brain metastases based on an actionable S100A9/RAGE resistance mechanism.

Authors:  Cátia Monteiro; Lauritz Miarka; María Perea-García; Neibla Priego; Pedro García-Gómez; Laura Álvaro-Espinosa; Ana de Pablos-Aragoneses; Natalia Yebra; Diana Retana; Patricia Baena; Coral Fustero-Torre; Osvaldo Graña-Castro; Kevin Troulé; Eduardo Caleiras; Patricia Tezanos; Pablo Muela; Elisa Cintado; José Luis Trejo; Juan Manuel Sepúlveda; Pedro González-León; Luis Jiménez-Roldán; Luis Miguel Moreno; Olga Esteban; Ángel Pérez-Núñez; Aurelio Hernández-Lain; José Mazarico Gallego; Irene Ferrer; Rocío Suárez; Eva M Garrido-Martín; Luis Paz-Ares; Celine Dalmasso; Elizabeth Cohen-Jonathan Moyal; Aurore Siegfried; Aisling Hegarty; Stephen Keelan; Damir Varešlija; Leonie S Young; Malte Mohme; Yvonne Goy; Harriet Wikman; Jose Fernández-Alén; Guillermo Blasco; Lucía Alcázar; Clara Cabañuz; Sergei I Grivennikov; Andrada Ianus; Noam Shemesh; Claudia C Faria; Rebecca Lee; Paul Lorigan; Emilie Le Rhun; Michael Weller; Riccardo Soffietti; Luca Bertero; Umberto Ricardi; Joaquim Bosch-Barrera; Elia Sais; Eduard Teixidor; Alejandro Hernández-Martínez; Alfonso Calvo; Javier Aristu; Santiago M Martin; Alvaro Gonzalez; Omer Adler; Neta Erez; Manuel Valiente
Journal:  Nat Med       Date:  2022-04-11       Impact factor: 87.241

3.  Prophylactic cranial irradiation reduces the incidence of brain metastasis in a mouse model of metastatic, HER2-positive breast cancer.

Authors:  Daniel L Smith; Bisrat G Debeb; Parmeswaran Diagaradjane; Richard Larson; Swaminathan Kumar; Jing Ning; Lara Lacerda; Li Li; Wendy A Woodward
Journal:  Genes Cancer       Date:  2021-03-13

4.  Animal models of brain metastasis.

Authors:  Lauritz Miarka; Manuel Valiente
Journal:  Neurooncol Adv       Date:  2021-11-27

Review 5.  Brain Metastasis Cell Lines Panel: A Public Resource of Organotropic Cell Lines.

Authors:  Manuel Valiente; Amanda E D Van Swearingen; Carey K Anders; Amos Bairoch; Adrienne Boire; Paula D Bos; Diana M Cittelly; Neta Erez; Gino B Ferraro; Dai Fukumura; Brunilde Gril; Meenhard Herlyn; Sheri L Holmen; Rakesh K Jain; Johanna A Joyce; Mihaela Lorger; Joan Massague; Josh Neman; Nicola R Sibson; Patricia S Steeg; Frits Thorsen; Leonie S Young; Damir Varešlija; Adina Vultur; Frances Weis-Garcia; Frank Winkler
Journal:  Cancer Res       Date:  2020-07-08       Impact factor: 12.701

6.  Lipocalin 2 promotes inflammatory breast cancer tumorigenesis and skin invasion.

Authors:  Emilly S Villodre; Xiaoding Hu; Richard Larson; Pascal Finetti; Kristen Gomez; Wintana Balema; Shane R Stecklein; Ginette Santiago-Sanchez; Savitri Krishnamurthy; Juhee Song; Xiaoping Su; Naoto T Ueno; Debu Tripathy; Steven Van Laere; François Bertucci; Pablo Vivas-Mejía; Wendy A Woodward; Bisrat G Debeb
Journal:  Mol Oncol       Date:  2021-08-27       Impact factor: 6.603

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.